The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

NNECOS Lunchtime Best Oncology Practice Series


Thursday, December 14th at 12:00 pm

Register for the Series!

Business of Oncology Practice

Missed this series? Recording available

eDUCATIONAL PROGRAM GRANTS

Learn more about our unique funding program

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • December 1 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma 
  • November 27 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphomaFDA approves nirogacestat for desmoid tumors 
  • November 16 - FDA approves capivasertib with fulvestrant for breast cancer
  • November 16 - FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
  • November 16 - FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma | FDA
  • November 15 - FDA approves repotrectinib for ROS1-positive non-small cell lung cancer | FDA
  • Oct 31 - FDA approves pembrolizumab with chemotherapy for biliary tract cancer
  • Oct 27 - FDA approves toripalimab-tpzi for nasopharyngeal carcinoma
  • Oct 24 - FDA approves ivosidenib for myelodysplastic syndromes
  • Oct 20 - FDA expands pediatric indication for entrectinib and approves new pellet formulation
  • Oct 16 - FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
  • Oct 13 - FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma
  • Oct. 11 - FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation 
  • Sept. 26 - FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia

  • Sept. 14 - FDA approves new and updated indications for temozolomide under Project Renewal 

Package/Label Updates

  • August - FDA approves new indication for  anemia without previous erythropoiesis stimulating agent use (ESAna├»ve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions

    Code Updates

    Other Updates


    CANCER COMMUNITY SUPPORT


    Looking Back!

    Enjoy this wonderful interview with 3 of NNECOS' founding members!



    Get Involved with a NNECOS Task Force


    SOCIAL MEDIA

     

    Upcoming events

    THANK YOU, FELLOW LIAISONS


    Thank You Corporate Members!


    New Job Posted - NNECOS Classifieds

    • UVM Cancer Center - Academic Clinician with experience in solid tumor oncology and immunotherapy

    • UVM Cancer Center - Tenure-track faculty member-Assistant Professor level.

    • UVM Cancer Center - Classical and Malignant Hematologist 

    • UVM Medical Center - Clinical Program Coordinator - Hematology 

    Group Practice Members

    Because your entire team benefits
    from being a part of NNECOS!


    Regional Educational Programs

    Emotional Wellbeing Throughout Your Cancer Journey 12.7.23.pdf



    Special thanks to our 2023 Diamond & Platinum Corporate Members!

       
       

     

     

    Platinum Members



     




     
       
           
        

    View the complete list of corporate members.

    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software